User:Mr. Ibrahem/Fosdenopterin

Fosdenopterin, sold under the brand name Nulibry, is a medication used to treat molybdenum cofactor deficiency (MoCD) type A. In people with this condition, it reduces the risk of death. It is given by gradual injection into a vein once per day.

Common side effects include complications related to the intravenous line, fever, respiratory infections, vomiting, gastroenteritis, and diarrhea. Other side effects may include sunburns. It is a manufactured form of cyclic pyranopterin monophosphate (cPMP), which it replaces.

Fosdenopterin was approved for medical use in the United States in 2021 and Europe in 2022. It is not approved in the United Kingdom as of 2022. In the United States it costs about 1,500 USD per 9.5 mg vial; a cost of about 550,000 USD for a 10 kg child for a year.